Evotec SE (EVOTF) Stock Analysis

Evotec SE (EVOTF) Healthcare & Pipeline Overview

Evotec SE, a global drug discovery and development partner, collaborates with pharmaceutical and biotechnology companies across diverse therapeutic areas, including diabetes, oncology, and immunology. Headquartered in Hamburg, Germany, Evotec leverages its research expertise and strategic partnerships to advance pharmaceutical innovation, operating in a competitive landscape with companies like BIOGY and CHIZF.

What Is the Investment Thesis for EVOTF?

Evotec SE presents a mixed investment case. While the company operates in a growing drug discovery and development market and has established partnerships with major pharmaceutical companies, its negative profit margin of -21.0% raises concerns about its financial performance. The company's collaborations with industry giants like Bayer and Pfizer provide revenue streams and validation of its research capabilities. However, the company's P/E ratio of -4.87 indicates it is not currently profitable. Upcoming catalysts include potential milestones from ongoing collaborations and advancements in its therapeutic programs. Investors should carefully weigh the growth potential against the current financial challenges.

Based on FMP financials and quantitative analysis

EVOTF Key Highlights

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry.

• The company has collaboration agreements with major pharmaceutical companies, including Bayer AG and Pfizer Inc.
• Evotec SE develops pharmaceutical products in various therapeutic areas, such as diabetes, oncology, and immunology.
• The company's market capitalization is $1.19B.
• Evotec SE has a negative profit margin of -21.0%.

Who Are EVOTF's Competitors?

EVOTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EVOTF's Key Strengths?

Strong partnerships with major pharmaceutical companies.

• Diverse portfolio of drug development programs.
• Expertise in multiple therapeutic areas.
• Established presence in the drug discovery and development market.

What Are EVOTF's Weaknesses?

Negative profit margin.

• Dependence on collaboration agreements for revenue.
• Exposure to regulatory risks.
• Competition from other drug discovery and development companies.

What Could Drive EVOTF Stock Higher?

Potential milestone payments from existing collaboration agreements.

• Advancements in proprietary drug development programs.
• Expansion of strategic partnerships with pharmaceutical companies.
• Positive clinical trial results for key drug candidates.

What Are the Key Risks for EVOTF?

Financial-distress signal — its Altman Z-Score of 0.35 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-26.5%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
• Failure to achieve milestones in collaboration agreements.
• Competition from other drug discovery and development companies.
• Patent expirations and generic drug competition.
• Regulatory risks and changes in healthcare policies.
• Negative clinical trial results for key drug candidates.

What Are the Growth Opportunities for EVOTF?

• Expansion of Strategic Partnerships: Evotec can expand its network of strategic partnerships with pharmaceutical and biotechnology companies. By forging new collaborations, Evotec can access additional funding, diversify its project portfolio, and leverage the expertise of its partners. Timeline: Ongoing.
• Advancement of Proprietary Drug Development Programs: Evotec can accelerate the development of its proprietary drug development programs. By investing in research and clinical trials, Evotec can bring novel therapies to market and generate substantial revenue streams. The global market for new drug approvals is projected to grow significantly, driven by unmet medical needs and technological advancements. Timeline: Ongoing.
• Geographic Expansion into Emerging Markets: Evotec can expand its geographic presence into emerging markets, such as Asia and Latin America. These markets offer significant growth opportunities due to their large populations, increasing healthcare spending, and unmet medical needs. By establishing operations in these regions, Evotec can tap into new revenue streams and diversify its geographic footprint. Timeline: 2-3 years.
• Leveraging Artificial Intelligence and Machine Learning: Evotec can leverage artificial intelligence (AI) and machine learning (ML) technologies to accelerate drug discovery and development. By using AI and ML, Evotec can identify promising drug candidates, optimize clinical trial designs, and improve the efficiency of its research processes. The global market for AI in drug discovery is projected to grow substantially, presenting a significant opportunity for Evotec to enhance its competitive advantage. Timeline: Ongoing.
• Focus on Personalized Medicine: Evotec can focus on developing personalized medicine solutions that are tailored to individual patients. By using genetic and other patient-specific information, Evotec can develop more effective and targeted therapies. The global market for personalized medicine is projected to grow rapidly, driven by advancements in genomics and diagnostics. Timeline: 3-5 years.

What Are EVOTF's Competitive Advantages?

• Established partnerships with major pharmaceutical companies.
• Expertise in drug discovery and development across various therapeutic areas.
• Proprietary technologies and platforms for drug discovery.
• Strong reputation and track record in the industry.

What Does EVOTF Do?

Evotec SE, established in 1993 and headquartered in Hamburg, Germany, operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Originally incorporated as Evotec AG, the company rebranded as Evotec SE in April 2019. Evotec's core business revolves around providing research services and developing pharmaceutical products across a broad spectrum of therapeutic areas. These areas include diabetes and its complications, fibrosis, infectious diseases, central nervous system (CNS) disorders, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. Evotec fosters strategic alliances with leading pharmaceutical companies, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, and Pfizer Inc., among others. These collaborations enable Evotec to leverage its research capabilities and contribute to the development of novel therapies. The company's extensive portfolio of partnerships underscores its position as a key player in the drug discovery and development ecosystem. Evotec's global reach extends to various regions, supporting pharmaceutical innovation on an international scale. With a focus on innovation and collaboration, Evotec continues to advance the development of new treatments for a wide range of diseases.

What Products and Services Does EVOTF Offer?

• Provides drug discovery services to pharmaceutical and biotechnology companies.
• Develops pharmaceutical products in various therapeutic areas.
• Conducts research and development activities.
• Engages in strategic collaborations with industry partners.
• Offers integrated drug discovery solutions.
• Focuses on therapeutic areas like diabetes, oncology, and immunology.
• Utilizes advanced technologies for drug discovery.

How Does EVOTF Make Money?

• Generates revenue through research and development collaborations with pharmaceutical and biotechnology companies.
• Receives milestone payments and royalties from partnered drug development programs.
• Provides fee-for-service research and development services.
• Develops and out-licenses proprietary drug candidates.

What Industry Does EVOTF Operate In?

Evotec SE operates within the drug manufacturing industry, specifically focusing on specialty and generic drugs. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Evotec competes with companies like BIOGY, CHIZF, and CMOPF, all vying for market share in drug discovery and development. The company's success depends on its ability to innovate, secure partnerships, and navigate the complex regulatory landscape.

Who Are EVOTF's Key Customers?

• Pharmaceutical companies.
• Biotechnology companies.
• Academic research institutions.
• Government research agencies.

Evotec SE has missed Wall Street's EPS estimate in 8 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 222.1% below estimates on average.

Evotec SE's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.35 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Evotec SE stands at -26.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -27.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -33.4%, the inverse of the P/E and a quick read on earnings relative to price.

Evotec SE (EVOTF) Valuation Context

Valued at $1.19B, EVOTF is classified as a small-cap stock.

EVOTF Revenue & Earnings Trend

In Q2 FY2026, EVOTF generated $166.2M in top-line revenue, marking a sequential decrease of 8.9%. The company recorded a net loss of $54.0M, with diluted EPS of $-0.30. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, EVOTF averaged $-0.32 in diluted EPS.

Company Profile

Evotec SE operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hamburg, DE. The company is led by CEO Christian Wojczewski. EVOTF has traded publicly since 2009.

EVOTF Financials

EVOTF Latest News

EVOTF Analyst Consensus

EVOTF MoonshotScore

Common Questions About EVOTF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources